Page 29 - The clinical aspects and management of chronic migraine Judith Anne Pijpers

70. Bøe MG, Mygland Å, Salvesen R. Prednisolone does not reduce withdrawal headache: A randomized, double-blind study. Neurology. 2007;69(1):26-31. doi:10.1212/01.wnl.0000263652.46222.e8
71. Descombes S, Brefel-Courbon C, Thalamas C, et al. Amitriptyline treatment in chronic drug-induced headache: A double-blind comparative pilot study. Headache. 2001;41(2):178-182. doi:10.1046/ j.1526-4610.2001.111006178.x
72. Johnson JL, Kwok YH, Sumracki NM, et al. Glial attenuation with ibudilast in the treatment of medication overuse headache: A double-blind, randomized, placebo-controlled pilot trial of efficacy and safety. Headache. 2015;55(9):1192-1208. doi:10.1111/head.12655
73. Grazzi L, Sansone E, Raggi A, et al. Mindfulness and pharmacological prophylaxis after withdrawal from medication overuse in patients with Chronic Migraine: an effectiveness trial with a one-year follow-up. J Headache Pain. 2017;18(1):15. doi:10.1186/s10194-017-0728-z
74. Diener H-C. Detoxification for medication overuse headache is not necessary. Cephalalgia. 2012;32(5):423-427. doi:10.1177/0333102411425867
75. Olesen J. Detoxification for medication overuse headache is the primary task. Cephalalgia. 2012;32(5):420-422. doi:10.1177/0333102411431309
76. Pirazzini M, Rossetto O, Eleopra R, Montecucco C. Botulinum Neurotoxins: Biology, Pharmacology, and Toxicology. Pharmacol Rev. 2017;69(2):200-235. doi:10.1124/pr.116.012658
77. Simpson DM, Hallett M, Ashman EJ, et al. Practice guideline update summary: Botulinum neurotoxin for the treatment of blepharospasm, cervical dystonia, adult spasticity, and headache: Report of the Guideline Development Subcommittee of the American Academy of Neurology. Neurology. 2016;86(19):1818-1826. doi:10.1212/WNL.0000000000002560
78. Jackson JL, Kuriyama A, Hayashino Y. Botulinum toxin A for prophylactic treatment of migraine and tension headaches in adults: a meta-analysis. JAMA. 2012;307(16):1736-1745. doi:10.1001/ jama.2012.505
79. Aurora SK, Dodick DW, Turkel CC, et al. OnabotulinumtoxinA for treatment of chronic migraine: results from the double-blind, randomized, placebo-controlled phase of the PREEMPT 1 trial. Cephalalgia. 2010;30(7):804-814. doi:10.1177/0333102410364676
80. Diener HC, Dodick DW, Aurora SK, et al. OnabotulinumtoxinA for treatment of chronic migraine: results from the double-blind, randomized, placebo-controlled phase of the PREEMPT 2 trial. Cephalalgia. 2010;30(7):804-814. doi:10.1177/0333102410364677
81. Dodick DW, Turkel CC, DeGryse RE, et al. OnabotulinumtoxinA for Treatment of Chronic Migraine: Pooled Results From the Double-Blind, Randomized, Placebo-Controlled Phases of the PREEMPT Clinical Program. Headache J Head Face Pain. 2010;50(6):921-936. doi:10.1111/j.1526- 4610.2010.01678.x
82. Dougherty C, Silberstein SD. Providing Care for Patients with Chronic Migraine: Diagnosis, Treatment, and Management. 2015;15(7):688-692.
83. Silberstein SD, Lipton RB, Dodick DW, et al. Efficacy and Safety of Topiramate for the Treatment of Chronic Migraine: A Randomized, Double-Blind, Placebo-Controlled Trial. Headache J Head Face Pain. 2007;47(2):170-180. doi:10.1111/j.1526-4610.2006.00684.x
84. Olesen J,Tfelt-Hansen P. Licence for Botox in so-called chronic migraine. Lancet. 2010;376(9755):1825- 1826. doi:10.1016/S0140-6736(10)62165-4
85. Solomon S. OnabotulinumtoxinA for treatment of chronic migraine: the unblinding problem. Headache. 2013;53(5):824-826. doi:10.1111/head.12065
86. Australian Government. Australian Public Assessment Report for Botulinum toxin Type A Proprietary Product Name : Botox. 2011;(June). https://www.tga.gov.au/sites/default/files/auspar- botox.pdf.
87. Finniss DG, Kaptchuk TJ, Miller F, Benedetti F. Biological, clinical, and ethical advances of placebo effects. Lancet. 2010;375(9715):686-695. doi:10.1016/S0140-6736(09)61706-2
88. Solomon S. Botulinum toxin for the treatment of chronic migraine: the placebo effect. Headache. 2011;51(6):980-984. doi:10.1111/j.1526-4610.2011.01915.x
89. Werkgroep Migraine Richtlijn NVN. Medicamenteuze behandeling migraine en MOH. Richtlijnen database Nvn. 2017.
1
General introduction
27